Full Text View
Tabular View
No Study Results Posted
Related Studies
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
This study has been completed.
Study NCT00153088   Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: September 9, 2005   Last Updated: September 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetic Nephropathies
Additional conditions recognized in this trial
Kidney Diseases
More general conditions related to this trial
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urologic Diseases
Interventions listed in this trial
Telmisartan capsule 40 mg
Placebo
Telmisartan capsule 80 mg
Additional drug interventions recognized in this trial
Telmisartan
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services